International PSC Study Group meeting Oslo, 14th – 15th June 2010
description
Transcript of International PSC Study Group meeting Oslo, 14th – 15th June 2010
![Page 1: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/1.jpg)
International PSC Study Group meetingOslo, 14th – 15th June 2010
International PSC database – parameter consensus
Kirsten Muri Boberg, OsloTobias Weismüller, Hannover
![Page 2: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/2.jpg)
2
International PSC database: Agenda• Purpose• Type/structure of database (3min-Talk of C. Ponsioen and of C. Bowlus)
• Organization of database• Responsibilities• Legal aspects/personal data protection• Costs• Parameters (3min-Talk of C. Schramm)
![Page 3: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/3.jpg)
3
International PSC database: Purpose• Provide key data for international collaborations
– Identification of specific subgroups for further studies • CCA, small-duct etc.
– DNA collections and genetic studies– Epidemiologic studies– Identification of clinical risk factors– Other?
![Page 4: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/4.jpg)
4
International PSC database: PurposeDiscussion
![Page 5: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/5.jpg)
5
International PSC database: Type & Structure• Should be constructed for robustness, durability and
flexibility– Upgrading should be possible– Avoid solutions like Access
• Accessable to all centers– One database, but automatic access only to own data (password)– Terminal server or web-based– Technology for access to the database must be available at each
center• Experiences?
– Local databases– German HEPNET-database– Nordic Liver Transplant Registry– Others?
![Page 6: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/6.jpg)
6
International PSC database: Type & Structure
3 min Talk of C. Ponsioen:
Dataset of the Epi PSC/PBC study
![Page 7: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/7.jpg)
7
International PSC database: Type & Structure
3 min Talk of C. Bowlus:
Online PSC-research network application
![Page 8: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/8.jpg)
8
International PSC database: Type & Structure
Discussion
![Page 9: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/9.jpg)
9
International PSC database: Organisation• Where will the database be located?• Link to local databases and biomaterials?
– (ID-number, see later)
• Who decides which data will be included?– Agreement on some data during this meeting– Additional suggestions can be co-ordinated and sent out
for a vote (accept if ≥50% agree?)
• Who decides on data access for specific projects?
![Page 10: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/10.jpg)
10
International PSC database: Organisation
INTERNATIONALDATABASE
A B C D E
Local databaseContact person
A
Local databaseContact person
D
Local databaseContact person
E
Local databaseContact person
C
Local databaseContact person
B
Centre A/B/C/D/E or PSC Study Group suggests a project to all centres
Centres that agree, participate
After approval from centre A/B/C/D, the centre taking the initiative to a study must contact the database co-ordinator to obtain the data
![Page 11: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/11.jpg)
11
International PSC database: Responsibilities• Co-ordination and follow-up
– Located to one center – Co-ordinator has access to all data– Access from all centers to own data only
• Responsibility for completeness and update– Each center
• Responsibility for the whole database– Steering committee?
![Page 12: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/12.jpg)
12
International PSC database: Organisation and Responsibilities
Discussion
![Page 13: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/13.jpg)
13
International PSC database: Legal aspects• Legal aspects must be cleared by each center
– Patients`consent– Ethical committee– Data processing
• Personal data protection– Identity of patient only known to the recruiting centre– Identification through an individual ID-Number (centre-code + patient code) (what is allowed?)– Secure internet connection
![Page 14: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/14.jpg)
14
International PSC database: Legal aspects
Discussion
![Page 15: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/15.jpg)
15
International PSC database: Costs• Non-recurring costs
– Development of database– Hardware (server, computer)
• Current costs– IT-technician– Study nurse– Co-ordinator
![Page 16: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/16.jpg)
16
International PSC database: Costs
Discussion
![Page 17: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/17.jpg)
17
International PSC database: Parameters• Aim for completeness of the parameters selected• Focus on a limited number (30? 40? 50?)• Local extensions or connections to other databases
should be the responsibility of each center
![Page 18: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/18.jpg)
18
![Page 19: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/19.jpg)
19
• Liver disease– Date first symptom– Date first biochemical abn.– Date diagnosis liver disease– Cholangiographical findings– Type of cholangiography– Malignancy (CCA, HCC etc)– Date diagnosis malignancy– Revised diagnosis liver– Date revised diagnosis
• IBD– Date first symptom– Date diagnosis IBD– Type of IBD– Date colectomy– Cause of colectomy– Malignancy– Date diagnosis malignancy
• Endpoints– Date OLT 1, 2, 3– Date of death– Cause of death
• Hepatitis serology• Smoking (at time of diagn.)• Alcohol (at time of diagn.)• Other autoimmune disorder in
the patient• Gall stone
• Comments
Main parameters in the Norwegian PSC biobank database
![Page 20: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/20.jpg)
20
• Liver disease– Date first symptom– Date first biochemical abn.– Date diagnosis liver disease– Cholangiographical findings– Type of cholangiography– Malignancy (CCA, HCC etc)– Date diagnosis malignancy– Revised diagnosis liver– Date revised diagnosis
• IBD– Date first symptom– Date diagnosis IBD– Type of IBD– Date colectomy– Cause of colectomy– Malignancy– Date diagnosis malignancy
• Endpoints– Date OLT 1, 2, 3– Date of death– Cause of death
• Hepatitis serology• Smoking (at time of diagn.)• Alcohol (at time of diagn.)• Other autoimmune disorder in
the patient• Gall stone
• Comments
Parameters: further discussion
![Page 21: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/21.jpg)
21
International PSC database: Type & Structure
3 min Talk of C. Schramm:
additional parameters: pregnancy in PSC
![Page 22: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/22.jpg)
22
International PSC database: Parameters• Liver disease
– Date first symptom– Date first biochemical abn.– Date diagnosis liver disease– Cholangiographical findings– Type of cholangiography– Malignancy (CCA, HCC etc)– Date diagnosis malignancy– Revised diagnosis liver– Date revised diagnosis
• IBD– Date first symptom– Date diagnosis IBD– Type of IBD– Date colectomy– Cause of colectomy– Malignancy– Date diagnosis malignancy
• Endpoints– Date OLT 1, 2, 3– Date of death– Cause of death
• Hepatitis serology• Smoking (at time of diagn.)• Alcohol (at time of diagn.)• Other autoimmune disorder in
the patient• Gall stone
• Comments
Discussion
![Page 23: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/23.jpg)
23
![Page 24: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/24.jpg)
24
• Main diagnosis liver disease– PSC– Small duct PSC– PSC/AIH ”overlap”– IgG4
• Date diagnosis liver disease– PSC: date first cholangiography
compatible with PSC– Small duct PSC: date when
collective findings give this conclusion (biopsy, cholangiography)
• Findings at cholangiography– Normal– IH + EH-PSC– IH-PSC (without EH-PSC)– EH-PSC (without IH-PSC)
• Hepatobiliary malignancy (confirmed by histology or cytology)
– None– CCA– CCA in situ (BilIN3) (in explanted
liver)– Gallbladder carcinoma– HCC– Pancreatic carcinoma– Other cancer in the liver region
(not classified within the above groups)
– Unknown
![Page 25: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/25.jpg)
25
• Date diagnosis IBD– Date colonoscopy with
macroscopic and/or microscopic findings compatible with IBD
• Type of IBD– None– UC– CD– IBD unclassified– Unknown
• Extension of IBD (macro/micro)– Left-sided (distal of left flexure)– Right-sided (prox. of left flexure)– Total colitis– Proctitis– Pouchitis
• Cause of colectomy– Active disease– Dysplasia (low-grade)– Dysplasia (high-grade/ca. in situ)– DALM (dysplasia associated
lesion or mass)– Colon carcinoma
• Malignancy, bowel– None– Dysplasia (low-grade)– Dysplasia (high-grade/ca. in situ)– DALM– Carcinoma– Unknown
![Page 26: International PSC Study Group meeting Oslo, 14th – 15th June 2010](https://reader035.fdocuments.net/reader035/viewer/2022062408/56813b63550346895da46172/html5/thumbnails/26.jpg)
26
• Date OLT (no. 1, 2, 3..)• Recurrence after OLT
• Date of death
• Cause of death– Liver failure– Hepatopancreaticobiliary cancer – Colon cancer– Other cancer– Other cause
• Smoking history (recorded at time of diagnosis liver disease)
– Yes – current smoker (regular use)
– Ex-smoker– Never smoker– Unknown
• Alcohol (recorded at time of diagnosis liver disease) (units/d)
– 0 – 1– >1 – 3– >3– Unknown
• Autoimmune disease in patient– DM type 1– Thyroid disease– Coeliac disease– Reumatoid arthritis– Sarcoidosis– Psoriatic disease– Nephritis– Vitiligo– SLE– Vasculitis– Fibrosing alveolitis– Sacroileitis